The pharmaceutical industry in fiscal year 2025 has arrived at a structural crossroads. As the industry navigates the post-pandemic recovery, the "Pharma 50"—a definitive ranking of the world’s top-selling therapeutic assets—reveals a clear shift in momentum. While legacy blockbusters face the inevitable erosion of patent cliffs and shifting market demands, a new cohort of specialty franchises is demonstrating that, when executed correctly, scale is not a plateau but a launchpad for sustained compounding growth.
The State of the Industry: A New Hierarchy
The headline narrative for FY2025 is defined by a high-stakes power struggle at the top of the leaderboard. Merck’s oncology titan, Keytruda, successfully defended its position as the No. 1 brand in the global pharmaceutical market, posting $31.68 billion in revenue. However, beneath this headline figure lies a more complex reality: at the molecule level, the combined weight of Eli Lilly’s tirzepatide (Mounjaro/Zepbound) and Novo Nordisk’s semaglutide (Ozempic/Wegovy) has effectively eclipsed the revenue generated by Keytruda.
This transition marks a tectonic shift in the pharmaceutical business model, moving from the long-term dominance of oncology checkpoints to the explosive, high-volume growth of cardiometabolic and weight-management therapies.
Chronology of Market Forces: From Pandemic Peak to Metabolic Surge
To understand the FY2025 rankings, one must analyze the industry’s trajectory over the past 24 months.
- Early 2024: The industry began to shed the massive revenues associated with COVID-19 products. Pfizer’s Paxlovid and Comirnaty began their expected decline, creating a revenue vacuum that companies scrambled to fill.
- Mid-2024: The "Metabolic Gold Rush" hit full stride. Supply chain constraints, which had plagued the launch of GLP-1 agonists in 2023, began to ease, allowing for the massive, double-digit growth seen in Mounjaro (up 99%) and Zepbound (up 174.9%).
- Late 2024–Early 2025: Investors shifted their focus from pure-play oncology to "specialty franchises." Drugs like AbbVie’s Skyrizi and Rinvoq, alongside Sanofi’s Dupixent, solidified their roles as the primary engines of industry growth, compounding value in the immunological space.
- Current Standing (FY2025): The industry has reached a "bifurcated stability." While the top-tier drugs are growing, the mid-tier is thinning as older, loss-of-exclusivity (LOE) assets like Humira, Revlimid, and Stelara experience significant, projected revenue contractions.
Supporting Data: Deep Dive into the Top 10
The data derived from primary corporate filings indicates that the top ten drugs alone account for a staggering portion of global pharmaceutical expenditure.
| Rank | Drug | Manufacturer | FY2025 ($M) | YoY Growth |
|---|---|---|---|---|
| 1 | Keytruda | Merck | 31,680 | 7.5% |
| 2 | Mounjaro | Eli Lilly | 22,965 | 99.0% |
| 3 | Ozempic | Novo Nordisk | 19,206 | 5.6% |
| 4 | Dupixent | Sanofi/Regeneron | 17,736 | 20.2% |
| 5 | Skyrizi | AbbVie | 17,562 | 49.9% |
| 6 | Eliquis | BMS/Pfizer | 14,443 | 8.3% |
| 7 | Darzalex | J&J | 14,351 | 23.0% |
| 8 | Biktarvy | Gilead Sciences | 14,300 | 6.7% |
| 9 | Zepbound | Eli Lilly | 13,542 | 174.9% |
| 10 | Wegovy | Novo Nordisk | 11,955 | 35.9% |
The most striking observation is the expansion of the immunological sector. While the overall pharma pipeline contracted in terms of the number of active programs in 2025, the immunological therapeutic bucket expanded by 20.6%. Assets like Skyrizi and Tremfya demonstrate that the market is currently rewarding assets that provide long-term, chronic management for inflammatory conditions.
The "Franchise Effect": Scaling vs. Plateauing
Industry analysts have long debated whether "blockbuster" drugs eventually hit a growth ceiling. The FY2025 data suggests that for top-tier franchises, the ceiling is higher than previously estimated.
Consider Dupixent, which continues to see strong double-digit growth (20.2%) despite having been on the market for several years. Similarly, Darzalex (J&J) continues to post 23% growth, proving that in oncology, as in immunology, depth of indication—gaining approval for more subsets of patients—is the primary driver of compounding revenue.
Conversely, we are witnessing the "patent cliff" effect in real-time. Humira dropped by 49.5%, Stelara by 41.3%, and Revlimid by 48.9%. These figures are not signs of clinical failure but of commercial life cycles coming to a close. The companies that successfully transitioned their pipelines (such as AbbVie moving from Humira to the Skyrizi/Rinvoq combo) are the ones maintaining their standing in the Pharma 50.
Official Responses and Strategic Pivot
Industry leaders have been vocal about the necessity of this shift. During recent earnings calls, executives from companies like Eli Lilly and Novo Nordisk have highlighted that their focus is no longer just on drug discovery, but on "manufacturing scale." The 99% growth for Mounjaro was not merely a result of clinical demand, but a direct consequence of massive investment in capacity.
"We have moved into an era where supply is as critical as science," noted one industry analyst. "The winners of 2025 are the companies that could turn their molecules into a reliable, high-volume commodity without sacrificing the premium nature of their brand."
Implications: What to Watch in 2026 and Beyond
The FY2025 landscape provides a roadmap for the next decade of pharmaceutical investment. Three key implications stand out:
1. The Death of the "Single-Indication" Blockbuster
The era of the "one-hit wonder" drug is effectively over. The drugs currently dominating the Pharma 50 are those with multi-indication potential—think of Keytruda’s dozens of oncology approvals or the expansion of GLP-1s into cardiovascular and sleep apnea treatments. Future R&D budgets will likely favor candidates that show broad therapeutic applicability.
2. The Weight of Weight-Loss
The sheer fiscal gravity of Mounjaro, Ozempic, Zepbound, and Wegovy has reshaped the entire industry. This is not just a trend; it is a fundamental reconfiguration of pharmaceutical spending. As these drugs become more affordable and insurance coverage broadens, the competition will shift from "clinical efficacy" to "price and access."
3. Immunological Resilience
Immunology has become the "safe harbor" of the industry. As noted in the data, the 20.6% expansion in this sector highlights a shift toward chronic care. Investors looking for stability in the face of patent cliffs are increasingly prioritizing companies with deep portfolios in dermatology, gastroenterology, and rheumatology.
4. The Exit of the COVID-19 "Windfall"
The decline of Paxlovid (down 58.7%) and Comirnaty (down 18.4%) signals the final normalization of the market. The industry has now fully absorbed the shock of the pandemic-era revenue spikes, and the current rankings reflect the "new normal" of a high-growth, high-stakes, and increasingly specialized pharmaceutical marketplace.
Conclusion
The Pharma 50 for FY2025 serves as a testament to the industry’s ability to adapt. While the top spot remains contested, the underlying metrics reveal an industry that is healthier than its raw growth numbers might suggest. By focusing on scaled specialty franchises, managing the transition of legacy assets off-patent, and leaning into the massive demand for cardiometabolic solutions, the world’s leading pharmaceutical companies are proving that they can navigate the dual pressures of intense regulatory scrutiny and the rapid obsolescence of their own best-selling products.
As we look toward FY2026, the question will not be whether these drugs can grow, but whether the infrastructure—both manufacturing and healthcare delivery—can keep pace with the unprecedented demand for these life-changing therapies. The leaderboard is shifting, and the pharmaceutical industry is moving with it, prioritizing longevity, scalability, and broad-spectrum impact above all else.
About the Author
